glp 1 agonist and heart failure Cardiovascular mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 agonists for heart failure:

55 KnyazevE

Using a double-blind, randomized, placebo-controlled design, we evaluated the effectiveness of daily CRWP (powder form: 0.5 g/kg for children 20 kg), compared with placebo (rice protein mimicking the protein load in the intervention group), on glutathione levels and ASD behaviors assessed using different behavioral scales such as Childhood Autism Rated Scale, Preschool Language Scale, Social Communication Questionnaire, Childhood Behavioral Checklist and the parent-rated Vineland Adaptive Behavior Scale, 2nd edition (VABS-II)

However, l-theanine or caffeine did not significantly affect reactivity of CEN compared to placebo

Enhanced ROS production and oxidative damage in subcutaneous white adipose tissue mitochondria in obese and type 2 diabetes subjects

Safety Considerations and Provider Guidance Before Starting GHK-Cu GHK-Cu is generally well-tolerated in published reports, but long-term human safety data is limited